Treatment with SI000413, a new herbal formula, ameliorates murine collagen-induced arthritis.
We tested the effects of SI000413, a new formula, consisting of Pyrolae herba and Trachelospermi caulis, on type II collagen-induced arthritis (CIA). CIA was induced in DBA/1J mice by immunization with bovine type II collagen (CII) on days 1 and 21. SI000413 was orally administered 3 times per week throughout the experiment and indomethacin was served as a positive control. Clinical scores, the count of arthritic legs, levels of interleukin 6 (IL-6) and anti-CII antibody, and lymphocyte subsets in blood were examined. SI000413 suppressed CIA development in a dose dependent manner and reduced the incidence of arthritic legs in mice. Histological analysis showed administration of SI000413 reduced inflammatory signs and cartilage destruction. Serum levels of IL-6 and anti-CII antibody were significantly decreased in SI000413-treated mice and the percentages of CD4 T cell, CD8 T cell and B cell in blood were restored to normal levels. In conclusion, we demonstrate that SI000413 ameliorates CIA both clinically and histologically and inhibits the production of anti-CII antibody and pro-inflammatory cytokine in the CIA mouse. These findings suggest that SI000413 is a potential new therapeutic herbal formula for the treatment of RA.
Park
Jee-Hun
JH
Life Science RD Center, Sinil Pharmaceutical Co Ltd, Chungju, Republic of Korea.
Lee
Jeong-Min
JM
Kim
Se-Na
SN
Lee
Seung-Ha
SH
Jun
Sung-Hoon
SH
You
Jae-Hoon
JH
Ahn
Kyoo-Seok
KS
Kang
Hee
H
D000818:Animals; D018501:Antirheumatic Agents / Q000737:chemistry / Q000494:pharmacology*; D001172:Arthritis, Rheumatoid / Q000139:chemically induced* / Q000473:pathology / Q000517:prevention & control*; D001323:Autoantibodies / Q000032:analysis / Q000096:biosynthesis; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects; D002356:Cartilage / Q000473:pathology; D002851:Chromatography, High Pressure Liquid; D024043:Collagen Type II / Q000276:immunology; D016207:Cytokines / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005434:Flow Cytometry; D005663:Furans / Q000032:analysis / Q000302:isolation & purification; D005960:Glucosides / Q000032:analysis / Q000302:isolation & purification; D015850:Interleukin-6 / Q000032:analysis / Q000096:biosynthesis; D007596:Joints / Q000473:pathology; D016131:Lymphocyte Subsets / Q000276:immunology; D008297:Male; D051379:Mice; D008811:Mice, Inbred DBA; D010936:Plant Extracts / Q000737:chemistry / Q000494:pharmacology*; D028321:Plant Preparations / Q000737:chemistry / Q000494:pharmacology*
D018501:Antirheumatic Agents; D001323:Autoantibodies; D024043:Collagen Type II; D016207:Cytokines; D005663:Furans; D005960:Glucosides; D015850:Interleukin-6; D010936:Plant Extracts; D028321:Plant Preparations; C531022:SI 000413; C077992:arctiin